Fibromyalgia is a chronic pain condition that can affect the entire body, often causing widespread pain, fatigue, sleep problems, and difficulties with concentration. Because symptoms can persist despite conventional treatment, interest has grown in whether ketamine therapy may offer another option for carefully selected patients.
Current research suggests that ketamine may provide short-term pain relief for some people with fibromyalgia, but the evidence remains limited. A 2024 systematic review identified only six studies involving 115 patients, while a broader Cochrane review published in 2025 concluded that available evidence for ketamine and related NMDA receptor antagonists in chronic pain is limited and ranges from low to very low certainty. These findings highlight both the potential and the unanswered questions surrounding ketamine for fibromyalgia.
What Is Fibromyalgia?
Fibromyalgia is a chronic condition characterized primarily by widespread musculoskeletal pain. However, the condition involves much more than sore muscles or aching joints. People with fibromyalgia may also experience persistent fatigue, nonrestorative sleep, headaches, sensitivity to touch, and cognitive symptoms sometimes described as “fibro fog.”
Researchers believe fibromyalgia involves changes in how the nervous system processes pain. This process, often called central sensitization, may cause the brain and spinal cord to become more sensitive to pain signals. As a result, sensations that might not be painful to other people can become uncomfortable or painful for someone with fibromyalgia.
Because fibromyalgia affects multiple aspects of the nervous system, successful treatment often requires a comprehensive approach rather than a single therapy.
What Is Ketamine Therapy?
Ketamine therapy involves the medical use of ketamine, a medication originally developed and widely used as an anesthetic. At lower, carefully controlled doses, ketamine has also been studied for certain chronic pain conditions and mental health disorders.
Ketamine works in part by blocking N-methyl-D-aspartate, or NMDA, receptors. These receptors are involved in the transmission and amplification of pain signals. By affecting NMDA receptor activity, ketamine may temporarily interrupt processes associated with heightened pain sensitivity and central sensitization.
Ketamine therapy for chronic pain may be administered in different ways depending on the clinical setting and treatment plan. Intravenous administration has been the most commonly studied approach in fibromyalgia research. Because ketamine can affect perception, blood pressure, and other body systems, treatment should involve appropriate medical screening, monitoring, and follow-up.
Can Ketamine Therapy Help Reduce Fibromyalgia Pain?
Ketamine therapy may help reduce fibromyalgia pain in some patients, particularly in the short term, but current research does not establish it as a proven long-term treatment. A 2024 systematic review found that several small studies reported short-term improvements in pain following ketamine treatment. However, the studies were limited in size, and longer-term benefits remain uncertain.
One randomized controlled trial found that some participants experienced substantial pain reduction shortly after an intravenous ketamine infusion, but the benefit did not translate into a significant long-term improvement during the eight-week follow-up period.
This distinction is important. A treatment that temporarily reduces pain may still have clinical value for selected patients, but short-term relief is not the same as a durable solution for a chronic condition.
Why Might Ketamine Affect Fibromyalgia Symptoms?
Ketamine may affect fibromyalgia symptoms because fibromyalgia is associated with altered pain processing and central sensitization. NMDA receptors play a role in how the nervous system responds to and amplifies certain pain signals.
By blocking these receptors, ketamine may reduce excessive nervous system activity involved in pain processing. Some researchers have suggested that this mechanism could make ketamine particularly relevant to chronic pain conditions involving central sensitization. However, fibromyalgia is a complex condition, and NMDA receptor activity is only one part of the broader biological processes involved.
Ketamine also has effects on several other neurotransmitter systems, which may contribute to its complex effects on pain perception. Researchers continue to study exactly which patients may be most likely to benefit and which treatment protocols, if any, can produce longer-lasting results.
How Strong Is the Research on Ketamine for Fibromyalgia?
The research on ketamine for fibromyalgia is still relatively limited. The 2024 systematic review included only six studies and a total of 115 patients. Most of the available studies examined short-term outcomes, and the studies varied in dosage, administration methods, and follow-up periods.
A broader Cochrane review published in 2025 examined ketamine and other NMDA receptor antagonists for chronic pain conditions, including fibromyalgia. The review found that the available evidence was insufficient to draw firm conclusions about ketamine’s effectiveness for reducing chronic pain intensity and called for larger, better-designed clinical trials.
For patients searching online for “ketamine therapy for fibromyalgia” or “ketamine treatment for chronic pain,” the most accurate conclusion is that the treatment is promising for some individuals but remains an area of ongoing research rather than a universally established solution.
What Are the Possible Risks and Side Effects of Ketamine Therapy?
Ketamine therapy can cause side effects, which is why appropriate medical evaluation and monitoring are important. Depending on the dose and method of administration, possible short-term effects can include changes in perception, dizziness, nausea, increased blood pressure, sedation, or dissociative experiences.
The 2024 fibromyalgia review reported that side effects were common during treatment in the included studies but generally resolved shortly after ketamine administration. However, the limited size and duration of available studies mean that more research is needed to better define long-term safety and the overall risk-benefit profile for chronic pain treatment.
The FDA has also warned about potential risks associated with compounded ketamine products, including formulations used outside appropriately supervised medical settings. Patients considering ketamine should discuss the source of the medication, the qualifications of the treating clinician, and the monitoring procedures involved in treatment.
Who May Be a Candidate for Ketamine Therapy for Fibromyalgia?
A candidate for ketamine therapy for fibromyalgia may be someone with persistent symptoms despite a comprehensive treatment approach, but candidacy should always be determined through an individualized medical evaluation. A clinician may consider the severity and duration of symptoms, previous treatments, other medical conditions, medications, and potential risks.
Ketamine therapy should not be viewed as a replacement for the broader management strategies commonly used for fibromyalgia. Physical activity adapted to the individual’s abilities, sleep management, behavioral and psychological approaches, and other evidence-based treatments may all play a role in a comprehensive care plan.
What Should Patients Ask Before Considering Ketamine Therapy?
Before considering ketamine therapy, patients should ask what treatment goals are realistic, how the treatment will be administered, how they will be monitored, and what evidence supports the recommended protocol. Patients should also ask about potential side effects, alternative treatment options, and the expected duration of any pain relief.
For individuals nearby or surrounding communities who are exploring advanced options for fibromyalgia and chronic pain, an evaluation with a qualified pain management specialist can help determine whether ketamine therapy or another treatment approach may be appropriate.
Can Ketamine Therapy Be Part of a Comprehensive Fibromyalgia Treatment Plan?
Ketamine therapy may become part of a comprehensive fibromyalgia treatment plan for carefully selected patients, but current evidence does not support presenting it as a guaranteed or permanent solution. Small studies suggest that ketamine can produce short-term pain relief in some patients, while larger and longer studies are still needed to clarify its long-term effectiveness and safety.
For patients living with widespread pain, fatigue, and other fibromyalgia symptoms, the most effective strategy is often individualized care that considers the many factors contributing to the condition. A thorough evaluation can help identify appropriate treatment options and establish realistic goals for improving pain, function, sleep, and overall quality of life.
This article is intended for educational purposes only and should not be considered medical advice. Ketamine therapy may not be appropriate for every patient. Diagnosis and treatment decisions should be made in consultation with a qualified healthcare professional.